| Douglas J Krell, MD | |
|
4705 Montgomery Ne, Suite 301-302, Albuquerque, NM 87109 | |
| (505) 254-6500 | |
| (505) 254-6532 |
| Full Name | Douglas J Krell |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 4705 Montgomery Ne, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043245061 | NPI | - | NPPES |
| 66206715 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 82234 (New Mexico) | Primary |
| Entity Name | San Carlos Apache Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265813075 PECOS PAC ID: 0648580597 Enrollment ID: O20151105002091 |
News Archive
Energy intake, particularly energy density, is positively associated with energy balance in patients with advanced cancer, report Swedish researchers.
A new guideline from the American Association of Neuromuscular & Electrodiagnostic Medicine and the American Academy of Neurology recommends guidance on how doctors should evaluate the full picture—from symptoms, family history, and ethnicity, to a physical exam and certain lab test results—in order to determine what genetic tests may best diagnose a person's subtype of limb-girdle or distal muscular dystrophy.
CombinatoRx, Incorporated, today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.
An international study looking at DNA from over 26,000 people has identified several genetic variants that substantially increase susceptibility to asthma in the population. The findings, published in the New England Journal of Medicine, will help scientists to focus their efforts to develop better therapies for the illness.
The National Comprehensive Cancer Network Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas J Krell, MD Po Box 27829, Albuquerque, NM 87125 Ph: (505) 232-1920 | Douglas J Krell, MD 4705 Montgomery Ne, Suite 301-302, Albuquerque, NM 87109 Ph: (505) 254-6500 |
News Archive
Energy intake, particularly energy density, is positively associated with energy balance in patients with advanced cancer, report Swedish researchers.
A new guideline from the American Association of Neuromuscular & Electrodiagnostic Medicine and the American Academy of Neurology recommends guidance on how doctors should evaluate the full picture—from symptoms, family history, and ethnicity, to a physical exam and certain lab test results—in order to determine what genetic tests may best diagnose a person's subtype of limb-girdle or distal muscular dystrophy.
CombinatoRx, Incorporated, today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.
An international study looking at DNA from over 26,000 people has identified several genetic variants that substantially increase susceptibility to asthma in the population. The findings, published in the New England Journal of Medicine, will help scientists to focus their efforts to develop better therapies for the illness.
The National Comprehensive Cancer Network Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
› Verified 2 days ago
Patrick R Mcginnis, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 5150 Journal Center Blvd Ne, Albuquerque, NM 87109 Phone: 505-727-7600 Fax: 505-727-7640 | |
Kelly Drescher, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 201 Cedar St Se Ste 5600, Albuquerque, NM 87106 Phone: 505-563-6000 Fax: 505-563-6060 | |
Dr. Jennifer Coffey Gill, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Presbyterian Healthcare Services, 6100 Pan American Freeway Ste 450, Albuquerque, NM 87109 Phone: 505-823-8787 Fax: 505-792-1978 | |
Shannon Carr, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2211 Lomas Blvd Ne, 4th Floor Ambulatory Care Ctr, Albuquerque, NM 87106 Phone: 505-272-2245 Fax: 505-272-1109 | |
Jacquelyn A Blackstone, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2211 Lomas Blvd Ne, Albuquerque, NM 87106 Phone: 505-272-3120 Fax: 505-272-8060 | |
Sophie Peterson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6100 Pan American Freeway, Ste 450, Albuquerque, NM 87109 Phone: 505-823-8787 Fax: 505-823-8788 |